Literature DB >> 16127082

Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice.

Leena Erkkilä1, Matti Jauhiainen, Kirsi Laitinen, Kristiina Haasio, Terttu Tiirola, Pekka Saikku, Maija Leinonen.   

Abstract

The effects of simvastatin treatment on Chlamydia pneumoniae lung infection, inflammation, and serum lipids in mouse model were studied. Simvastatin decreased viable chlamydial counts and increased inflammatory cell infiltrates in the lung tissue, suggesting that simvastatin treatment had both antichlamydial and immunomodulatory effects during an acute C. pneumoniae infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127082      PMCID： PMC1195438          DOI： 10.1128/AAC.49.9.3959-3962.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  40 in total

1.  In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products.

Authors:  L Diomede; D Albani; M Sottocorno; M B Donati; M Bianchi; P Fruscella; M Salmona
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-08       Impact factor: 8.311

2.  Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.

Authors:  P A Kiener; P M Davis; J L Murray; S Youssef; B M Rankin; M Kowala
Journal:  Int Immunopharmacol       Date:  2001-01       Impact factor: 4.932

Review 3.  Statins as anti-inflammatory agents.

Authors:  Gabriele Weitz-Schmidt
Journal:  Trends Pharmacol Sci       Date:  2002-10       Impact factor: 14.819

4.  Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin.

Authors:  R Stanislaus; K Pahan; A K Singh; I Singh
Journal:  Neurosci Lett       Date:  1999-07-09       Impact factor: 3.046

5.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F M Sacks; L A Moye; S Goldman; G C Flaker; E Braunwald
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

6.  The effect of statins on mortality in patients with bacteremia.

Authors:  A P Liappis; V L Kan; C G Rochester; G L Simon
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

7.  Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin.

Authors:  Diethard Pruefer; Joachim Makowski; Martin Schnell; Ute Buerke; Manfred Dahm; Hellmut Oelert; Ulf Sibelius; Ulrich Grandel; Friedrich Grimminger; Werner Seeger; Jürgen Meyer; Harald Darius; Michael Buerke
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

8.  Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.

Authors:  C L Bisgaier; A D Essenburg; B J Auerbach; M E Pape; C S Sekerke; A Gee; S Wölle; R S Newton
Journal:  J Lipid Res       Date:  1997-12       Impact factor: 5.922

9.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F Sacks; E Braunwald
Journal:  Circulation       Date:  1999-07-20       Impact factor: 29.690

10.  Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction.

Authors:  Julie K Plenge; Teri L Hernandez; Kathleen M Weil; Paul Poirier; Gary K Grunwald; Santica M Marcovina; Robert H Eckel
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690
View more
  17 in total

1.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

Review 2.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

Review 3.  The Use of Statins and Risk of Community-Acquired Pneumonia.

Authors:  Mohammed A Batais; Abdur Rahman Khan; Aref A Bin Abdulhak
Journal:  Curr Infect Dis Rep       Date:  2017-08       Impact factor: 3.725

4.  Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.

Authors:  Kama Z Guluma; Paul A Lapchak
Journal:  Brain Res       Date:  2010-07-29       Impact factor: 3.252

Review 5.  Is There Potential for Repurposing Statins as Novel Antimicrobials?

Authors:  Emma Hennessy; Claire Adams; F Jerry Reen; Fergal O'Gara
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 6.  Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.

Authors:  Jason Munguia; Victor Nizet
Journal:  Trends Pharmacol Sci       Date:  2017-03-08       Impact factor: 14.819

7.  Cholesterol suppresses antimicrobial effect of statins.

Authors:  Mohammad Reza Haeri; Kenneth White; Mohammad Qharebeglou; Malek Moein Ansar
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

8.  Inhibition of HMGCoA reductase by simvastatin protects mice from injurious mechanical ventilation.

Authors:  Nikolaos Manitsopoulos; Stylianos E Orfanos; Anastasia Kotanidou; Ioanna Nikitopoulou; Ilias Siempos; Christina Magkou; Ioanna Dimopoulou; Spyros G Zakynthinos; Apostolos Armaganidis; Nikolaos A Maniatis
Journal:  Respir Res       Date:  2015-02-14

9.  Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape.

Authors:  Suraj P Parihar; Reto Guler; Dirk M Lang; Harukazu Suzuki; A David Marais; Frank Brombacher
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

10.  The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection.

Authors:  Emma Hennessy; Julie O'Callaghan; Marlies J Mooij; Claire Legendre; Olga Camacho-Vanegas; Sandra C Camacho; Claire Adams; John A Martignetti; Fergal O'Gara
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.